3rd Quarter - Amendment

PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
—
Expenses
$107,700
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 31, 2012 $107,700 Replaced
3rd Quarter - Amendment Dec 4, 2012 $107,700 Replaced
3rd Quarter - Amendment (this page) Dec 4, 2012 $107,700 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Annual pharmaceutical fee, 340B discount drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, FDASIA, comparative effectiveness research

Foreign entity interest: Grifols S.A.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
JOHN EVERETT CROSLAND —
KYM HOWARTH KILBOURNE —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.